Δ9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test

Involvement of cannabinoid CB1 receptor and serotonergic system

Nobuaki Egashira, Tomomi Matsuda, Emi Koushi, Fuminori Higashihara, Kenichi Mishima, Shozo Chidori, Nobuyoshi Hasebe, Katsunori Iwasaki, Ryoji Nishimura, Ryozo Oishi, Michihiro Fujiwara

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In the present study, we investigated the effect of Δ9-tetrahydrocannabinol (THC), the principal psychoactive component of marijuana, on immobility time during the forced swim test. THC (2 and 6 mg/kg, i.p.) significantly prolonged the immobility time. In addition, THC at the same doses did not significantly affect locomotor activity in the open-field test. The selective cannabinoid CB1 receptor antagonist rimonabant (3 mg/kg, i.p.) significantly reduced the enhancement of immobility by THC (6 mg/kg). Similarly, the selective serotonin (5-HT) reuptake inhibitor (SSRI) citalopram (10 mg/kg, i.p.) and 5-HT1A/7 receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.3 mg/kg, i.p.) significantly reduced this THC-induced effect. Moreover, the selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide dihydrochloride (WAY100635, 1 mg/kg, i.p.) and the postsynaptic 5-HT1A receptor antagonist MM-77 (0.1 mg/kg, i.p.) reversed this reduction effect of 8-OH-DPAT (0.3 mg/kg). In contrast, the selective 5-HT7 receptor antagonist (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride (SB269970) had no effect on this reduction effect of 8-OH-DPAT. WAY100635 (1 mg/kg) also reversed the reduction effect of citalopram (10 mg/kg). These findings suggest that the 5-HT1A receptors are involved in THC-induced enhancement of immobility.

Original languageEnglish
Pages (from-to)117-121
Number of pages5
JournalEuropean Journal of Pharmacology
Volume589
Issue number1-3
DOIs
Publication statusPublished - Jul 28 2008

Fingerprint

Cannabinoid Receptor CB1
Dronabinol
8-Hydroxy-2-(di-n-propylamino)tetralin
Receptor, Serotonin, 5-HT1A
Serotonin 5-HT1 Receptor Antagonists
Citalopram
rimonabant
Serotonin
Cannabinoid Receptor Antagonists
Cannabis
Locomotion
hydroxide ion

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Δ9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test : Involvement of cannabinoid CB1 receptor and serotonergic system. / Egashira, Nobuaki; Matsuda, Tomomi; Koushi, Emi; Higashihara, Fuminori; Mishima, Kenichi; Chidori, Shozo; Hasebe, Nobuyoshi; Iwasaki, Katsunori; Nishimura, Ryoji; Oishi, Ryozo; Fujiwara, Michihiro.

In: European Journal of Pharmacology, Vol. 589, No. 1-3, 28.07.2008, p. 117-121.

Research output: Contribution to journalArticle

Egashira, N, Matsuda, T, Koushi, E, Higashihara, F, Mishima, K, Chidori, S, Hasebe, N, Iwasaki, K, Nishimura, R, Oishi, R & Fujiwara, M 2008, 'Δ9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: Involvement of cannabinoid CB1 receptor and serotonergic system', European Journal of Pharmacology, vol. 589, no. 1-3, pp. 117-121. https://doi.org/10.1016/j.ejphar.2008.03.046
Egashira, Nobuaki ; Matsuda, Tomomi ; Koushi, Emi ; Higashihara, Fuminori ; Mishima, Kenichi ; Chidori, Shozo ; Hasebe, Nobuyoshi ; Iwasaki, Katsunori ; Nishimura, Ryoji ; Oishi, Ryozo ; Fujiwara, Michihiro. / Δ9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test : Involvement of cannabinoid CB1 receptor and serotonergic system. In: European Journal of Pharmacology. 2008 ; Vol. 589, No. 1-3. pp. 117-121.
@article{cb28414d372e47a0815870f3c99f4119,
title = "Δ9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: Involvement of cannabinoid CB1 receptor and serotonergic system",
abstract = "In the present study, we investigated the effect of Δ9-tetrahydrocannabinol (THC), the principal psychoactive component of marijuana, on immobility time during the forced swim test. THC (2 and 6 mg/kg, i.p.) significantly prolonged the immobility time. In addition, THC at the same doses did not significantly affect locomotor activity in the open-field test. The selective cannabinoid CB1 receptor antagonist rimonabant (3 mg/kg, i.p.) significantly reduced the enhancement of immobility by THC (6 mg/kg). Similarly, the selective serotonin (5-HT) reuptake inhibitor (SSRI) citalopram (10 mg/kg, i.p.) and 5-HT1A/7 receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.3 mg/kg, i.p.) significantly reduced this THC-induced effect. Moreover, the selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide dihydrochloride (WAY100635, 1 mg/kg, i.p.) and the postsynaptic 5-HT1A receptor antagonist MM-77 (0.1 mg/kg, i.p.) reversed this reduction effect of 8-OH-DPAT (0.3 mg/kg). In contrast, the selective 5-HT7 receptor antagonist (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride (SB269970) had no effect on this reduction effect of 8-OH-DPAT. WAY100635 (1 mg/kg) also reversed the reduction effect of citalopram (10 mg/kg). These findings suggest that the 5-HT1A receptors are involved in THC-induced enhancement of immobility.",
author = "Nobuaki Egashira and Tomomi Matsuda and Emi Koushi and Fuminori Higashihara and Kenichi Mishima and Shozo Chidori and Nobuyoshi Hasebe and Katsunori Iwasaki and Ryoji Nishimura and Ryozo Oishi and Michihiro Fujiwara",
year = "2008",
month = "7",
day = "28",
doi = "10.1016/j.ejphar.2008.03.046",
language = "English",
volume = "589",
pages = "117--121",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Δ9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test

T2 - Involvement of cannabinoid CB1 receptor and serotonergic system

AU - Egashira, Nobuaki

AU - Matsuda, Tomomi

AU - Koushi, Emi

AU - Higashihara, Fuminori

AU - Mishima, Kenichi

AU - Chidori, Shozo

AU - Hasebe, Nobuyoshi

AU - Iwasaki, Katsunori

AU - Nishimura, Ryoji

AU - Oishi, Ryozo

AU - Fujiwara, Michihiro

PY - 2008/7/28

Y1 - 2008/7/28

N2 - In the present study, we investigated the effect of Δ9-tetrahydrocannabinol (THC), the principal psychoactive component of marijuana, on immobility time during the forced swim test. THC (2 and 6 mg/kg, i.p.) significantly prolonged the immobility time. In addition, THC at the same doses did not significantly affect locomotor activity in the open-field test. The selective cannabinoid CB1 receptor antagonist rimonabant (3 mg/kg, i.p.) significantly reduced the enhancement of immobility by THC (6 mg/kg). Similarly, the selective serotonin (5-HT) reuptake inhibitor (SSRI) citalopram (10 mg/kg, i.p.) and 5-HT1A/7 receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.3 mg/kg, i.p.) significantly reduced this THC-induced effect. Moreover, the selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide dihydrochloride (WAY100635, 1 mg/kg, i.p.) and the postsynaptic 5-HT1A receptor antagonist MM-77 (0.1 mg/kg, i.p.) reversed this reduction effect of 8-OH-DPAT (0.3 mg/kg). In contrast, the selective 5-HT7 receptor antagonist (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride (SB269970) had no effect on this reduction effect of 8-OH-DPAT. WAY100635 (1 mg/kg) also reversed the reduction effect of citalopram (10 mg/kg). These findings suggest that the 5-HT1A receptors are involved in THC-induced enhancement of immobility.

AB - In the present study, we investigated the effect of Δ9-tetrahydrocannabinol (THC), the principal psychoactive component of marijuana, on immobility time during the forced swim test. THC (2 and 6 mg/kg, i.p.) significantly prolonged the immobility time. In addition, THC at the same doses did not significantly affect locomotor activity in the open-field test. The selective cannabinoid CB1 receptor antagonist rimonabant (3 mg/kg, i.p.) significantly reduced the enhancement of immobility by THC (6 mg/kg). Similarly, the selective serotonin (5-HT) reuptake inhibitor (SSRI) citalopram (10 mg/kg, i.p.) and 5-HT1A/7 receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.3 mg/kg, i.p.) significantly reduced this THC-induced effect. Moreover, the selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide dihydrochloride (WAY100635, 1 mg/kg, i.p.) and the postsynaptic 5-HT1A receptor antagonist MM-77 (0.1 mg/kg, i.p.) reversed this reduction effect of 8-OH-DPAT (0.3 mg/kg). In contrast, the selective 5-HT7 receptor antagonist (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride (SB269970) had no effect on this reduction effect of 8-OH-DPAT. WAY100635 (1 mg/kg) also reversed the reduction effect of citalopram (10 mg/kg). These findings suggest that the 5-HT1A receptors are involved in THC-induced enhancement of immobility.

UR - http://www.scopus.com/inward/record.url?scp=47549084403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549084403&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.03.046

DO - 10.1016/j.ejphar.2008.03.046

M3 - Article

VL - 589

SP - 117

EP - 121

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -